Company intelligence / Profile preview
Selecta Biosciences
Watertown, Massachusetts, United Statesprnewswire.com ↗
- Ownership
- Public · SELB
- Employees
- ~200
- Development stage
- Phase 2
01
Overview
Selecta’s lead program SEL‑212 reached Phase 3 trials for chronic refractory gout. The company’s ImmTOR™ platform has shown promise in inducing immune tolerance to enable repeat dosing of gene therapies and improve outcomes for autoimmune indications. In late 2023, Selecta merged with Cartesian Therapeutics; the combined company now focuses on pioneering RNA cell therapy for autoimmune disease, advancing programs such as Descartes‑08 in myasthenia gravis
- Therapeutic areas
- ImmunologyRare DiseasesRheumatology
- Modalities
- Nanoparticle immunomodulatory drugsGene therapies (AAV-based)Enzyme therapiesRNA cell therapy (post-merger focus)
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
Asklepios BioPharmaceutical, Inc. (“AskBio”)—strategic partnership combining AAV gene therapy platformsAstellas Gene Therapies—license agreement for Xork IgG protease candidate targeting Pompe disease
04
Financials
- Market cap
- $135.2M
- Total revenue
- $0
- Enterprise value
- $-1.4M
Beyond the preview
Go deeper on Selecta Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selecta Biosciences.